Johnson Pharmacare (532154) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
11 Jun, 2026Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2025, at the meeting held on July 23, 2025.
Financial highlights
Reported a net loss of Rs. 5.34 lakhs for the quarter ended June 30, 2025, compared to a net loss of Rs. 3.99 lakhs in the same quarter last year.
Total income for the quarter was Rs. 0.30 lakhs, down from Rs. 0.90 lakhs in the previous quarter.
Total expenses for the quarter were Rs. 5.34 lakhs, compared to Rs. 3.99 lakhs in the same quarter last year.
Earnings per share (EPS) for the quarter stood at Rs. (0.00), unchanged from the previous quarter.
Key financial ratios and metrics
Paid-up equity share capital remained at Rs. 5,500.00 lakhs.
Other equity as of March 31, 2025, was Rs. 116.91 lakhs.
Latest events from Johnson Pharmacare
- Net loss increased to ₹110.31 lakhs on flat revenue, with EPS at ₹(0.02) for the quarter.532154
Q1 26/27 - FY26 saw a sharp net loss, negative cash flows, and major doubts about financial viability.532154Q4 25/26
- New auditor and independent director appointed, with all regulatory confirmations in place.532154Q3 25/26
- No revenue and continued net losses reported for the quarter ended September 30, 2025.532154Q2 25/26
- Net loss narrowed for Q2 and H1 FY25, with negligible revenue and stable equity.532154Q2 24/25
- Net loss of ₹3.99 lakhs on revenue of ₹3.99 lakhs reported for Q1 FY25.532154Q1 24/25
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/25
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/25